Vistagen Therapeutics (VTGN) Competitors $2.34 0.00 (0.00%) As of 02:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTGN vs. TERN, ACB, SLDB, ATXS, SLRN, CDTX, HUMA, DRUG, LFCR, and ALMSShould you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Terns Pharmaceuticals (TERN), Aurora Cannabis (ACB), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Acelyrin (SLRN), Cidara Therapeutics (CDTX), Humacyte (HUMA), Bright Minds Biosciences (DRUG), Lifecore Biomedical (LFCR), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. Vistagen Therapeutics vs. Terns Pharmaceuticals Aurora Cannabis Solid Biosciences Astria Therapeutics Acelyrin Cidara Therapeutics Humacyte Bright Minds Biosciences Lifecore Biomedical Alumis Terns Pharmaceuticals (NASDAQ:TERN) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability. Which has more risk & volatility, TERN or VTGN? Terns Pharmaceuticals has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Do analysts rate TERN or VTGN? Terns Pharmaceuticals currently has a consensus price target of $18.38, indicating a potential upside of 427.26%. Given Terns Pharmaceuticals' higher probable upside, analysts clearly believe Terns Pharmaceuticals is more favorable than Vistagen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Vistagen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Which has preferable earnings and valuation, TERN or VTGN? Vistagen Therapeutics has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Vistagen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$90.21M-$1.13-3.08Vistagen Therapeutics$698K96.76-$29.36M-$1.48-1.58 Do insiders and institutionals have more ownership in TERN or VTGN? 98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are held by institutional investors. 15.1% of Terns Pharmaceuticals shares are held by company insiders. Comparatively, 1.3% of Vistagen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer TERN or VTGN? Vistagen Therapeutics received 239 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 59.72% of users gave Terns Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTerns PharmaceuticalsOutperform Votes4359.72% Underperform Votes2940.28% Vistagen TherapeuticsOutperform Votes28272.31% Underperform Votes10827.69% Does the media prefer TERN or VTGN? In the previous week, Terns Pharmaceuticals had 4 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 7 mentions for Terns Pharmaceuticals and 3 mentions for Vistagen Therapeutics. Vistagen Therapeutics' average media sentiment score of 1.74 beat Terns Pharmaceuticals' score of 1.48 indicating that Vistagen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vistagen Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is TERN or VTGN more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -6,777.08%. Terns Pharmaceuticals' return on equity of -32.76% beat Vistagen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -32.76% -31.33% Vistagen Therapeutics -6,777.08%-48.12%-43.80% SummaryTerns Pharmaceuticals and Vistagen Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTGN vs. The Competition Export to ExcelMetricVistagen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.54M$6.74B$5.50B$7.96BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-1.587.3822.6318.55Price / Sales96.76241.88397.30103.38Price / CashN/A65.8538.1834.62Price / Book0.836.476.704.25Net Income-$29.36M$143.68M$3.23B$248.27M7 Day PerformanceN/A1.85%1.36%1.28%1 Month PerformanceN/A6.73%3.85%3.75%1 Year Performance-50.63%-2.72%15.87%5.31% Vistagen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTGNVistagen Therapeutics1.8213 of 5 stars$2.34flatN/A-51.6%$67.54M$698,000.00-1.5840News CoveragePositive NewsTERNTerns Pharmaceuticals4.2798 of 5 stars$2.71+12.9%$18.38+578.0%-34.7%$236.58MN/A-2.3040Positive NewsACBAurora Cannabis0.6363 of 5 stars$4.20-5.4%N/A-49.7%$236.10M$320.81M84.021,340News CoverageSLDBSolid Biosciences3.9803 of 5 stars$3.03+18.8%$15.67+417.1%-62.7%$234.80M$8.09M-1.00100High Trading VolumeATXSAstria Therapeutics2.5439 of 5 stars$4.11+1.7%$26.60+547.2%-43.8%$231.94MN/A-1.9730Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageSLRNAcelyrin2.9976 of 5 stars$2.28+3.6%$9.60+321.1%-40.9%$230.07MN/A-0.93135Positive NewsCDTXCidara Therapeutics4.2494 of 5 stars$20.69+6.4%$39.14+89.2%+74.4%$226.62M$1.28M-0.8190Upcoming EarningsAnalyst ForecastNews CoverageHUMAHumacyte2.807 of 5 stars$1.45-13.7%$13.71+845.8%-63.0%$224.92M$1.57M-1.08150News CoverageDRUGBright Minds Biosciences3.3208 of 5 stars$31.89-3.7%$84.33+164.5%+2,970.0%$224.63MN/A-187.58N/ANews CoveragePositive NewsLFCRLifecore Biomedical1.6419 of 5 stars$6.04-5.8%$8.00+32.5%+5.3%$223.63M$130.86M-10.79690ALMSAlumis2.5255 of 5 stars$4.70-6.0%$26.00+453.2%N/A$221.94MN/A0.00N/AAnalyst ForecastGap Down Related Companies and Tools Related Companies TERN Alternatives ACB Alternatives SLDB Alternatives ATXS Alternatives SLRN Alternatives CDTX Alternatives HUMA Alternatives DRUG Alternatives LFCR Alternatives ALMS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTGN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vistagen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTGN Stock Free VTGN Stock Alerts